Sep 30, 2026 · 14 min · 8 segments
This episode explores how emerging interferon-targeted therapies may reshape the treatment of cutaneous lupus erythematosus (CLE). Using a clinical scenario, it explores when earlier use of targeted…
Victoria WerthGuestAnd so thinking about this patient, this is a patient with CLE, but if you think about SLE with cutaneous manifestations, we do have an approved agent, anafrolumab, and I would like to hear how the availability of anafrolumab has changed how you treat patients with SLE with prominent skin manifestations.
Yeah, so I think that anaphylumab has completely changed the approach to cutaneous lupus that is seen in an SLE patient.
And if a patient is really suffering from what I would characterize as moderate or severe disease, I think very quickly now anaphylumab is being offered.
And as we learn more about them and compare them, I think it will lead to really interesting dialogues about what types of approaches patients will want to take.
And when I think about anaphralomab and inhibiting signaling through the type 1 interferon receptor, one of the side effects that came out in the pivotal trials, there was a greater number of participants who developed herpes zoster in the anaphylumab group versus the placebo group on background therapy.
And there's things that we can do ahead of time to mitigate that happening, right, such as vaccinations that we can offer our patients.
So always important to keep those key safety issues in mind and what we can do to help our patients.
And so thinking about this patient, this is a patient with CLE, but if you think about SLE with cutaneous manifestations, we do have an approved agent, anafrolumab, and I would like to hear how the availability of anafrolumab has changed how you treat patients with SLE with prominent skin manifestations.
Yeah, so I think that anaphylumab has completely changed the approach to cutaneous lupus that is seen in an SLE patient.
And if a patient is really suffering from what I would characterize as moderate or severe disease, I think very quickly now anaphylumab is being offered.
And as we learn more about them and compare them, I think it will lead to really interesting dialogues about what types of approaches patients will want to take.
And when I think about anaphralomab and inhibiting signaling through the type 1 interferon receptor, one of the side effects that came out in the pivotal trials, there was a greater number of participants who developed herpes zoster in the anaphylumab group versus the placebo group on background therapy.
And there's things that we can do ahead of time to mitigate that happening, right, such as vaccinations that we can offer our patients.
So always important to keep those key safety issues in mind and what we can do to help our patients.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
